Combined strategies for tumor immunotherapy with nanoparticles

A brief review of tumor immunotherapies shows significant advancements in academic research and preclinical studies. Analysis of different immune cell pathways, including macrophage activation, natural killer cells, and dendritic cell presentation show promising clinical results when targeted with d...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & translational oncology 2019-11, Vol.21 (11), p.1441-1449
Main Authors: Savitsky, K., Yu, X.
Format: Article
Language:English
Subjects:
Antigens, Neoplasm
Antineoplastic Agents - therapeutic use
Clinical Trials as Topic
Combined Modality Therapy - methods
Dendritic Cells - immunology
Docetaxel - therapeutic use
Doxorubicin - therapeutic use
Galectin 1 - antagonists & inhibitors
Gold - therapeutic use
Humans
Immunity, Cellular
Immunity, Humoral
Immunotherapy - methods
Killer Cells, Natural - immunology
Lymphocyte Activation
Macrophage Activation
Medicine
Medicine & Public Health
Nanoparticles - administration & dosage
Nanoparticles - therapeutic use
Neoplasms - immunology
Neoplasms - therapy
Oncology
Organ Specificity
Paclitaxel - therapeutic use
Receptors, Chimeric Antigen - immunology
Review Article
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A brief review of tumor immunotherapies shows significant advancements in academic research and preclinical studies. Analysis of different immune cell pathways, including macrophage activation, natural killer cells, and dendritic cell presentation show promising clinical results when targeted with different nanoparticle polymer and gold materials. Following a brief discussion on immuno-oncology successes, detailed results are discussed in macrophage activation, dendritic cell presentation, and lysis of tumor cells with natural killer cells. Common targets include tumor-associated macrophages and induction of the proinflammatory phenotype, dual targeting of cell and humoral immunity with dendritic cells, and creating chimeric antigen receptors on natural killer cells. An analysis of the results shows a variety of nanoparticle synthesis methods are required depending on drug type and tissue type affected by tumors. Future research is discussed in conjunction with a brief analysis of completed clinical trial data on cancer therapies using nanoparticles to date. Although paclitaxel-loaded albumin nanoparticles are most frequently studied, academic research shows there may be additional mechanisms of action to elicit anti-tumor activity.
ISSN:1699-048X
1699-3055
DOI:10.1007/s12094-019-02081-3